Previous 10 | Next 10 |
home / stock / onc:cc / onc:cc news
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Canada NewsWire Conference call and webcast to take place on Thursday, May 5, 2022 , at 5:00 p.m. ET SAN DIEGO and CALGAR...
Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire SAN DIEGO, Calif. and CALGARY, AB , April...
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are...
Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine Canada NewsWire - Pelareorep-CAR T combination may exp...
Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference Canada NewsWire SAN DIEGO, Calif. and CALGARY, AB , April 12, 2022 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC...
Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting Canada NewsWire - Results demonstrate meaningful and durable efficacy signal in a highly challenging indication - A higher...
Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress Canada NewsWire SAN DIEGO, Calif. and CALGARY, AB , April 6, 2022 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, inc...
Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial Canada NewsWire Independent review identified, no safety concerns in trial's final safety run-...
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diag...
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort Canada NewsWire First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated ...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONC:CC Stock Symbol:
TSXC Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program PR Newswire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence PR Newswire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...